2024-03-28 13:18:08 ET
Medigene AG (MDGEF)
Full Year 2023 Earnings Conference Call
March 28, 2024 10:00 AM ET
Company Participants
Pamela Keck – Head-Investor Relations
Selwyn Ho – Chief Executive Officer
Conference Call Participants
Sara Nik – H.C. Wainwright
Presentation
Operator
Ladies and gentlemen, welcome to the Medigene AG Full Year 2023 Earnings Call and Live Webcast. I am Sandra, the Chorus Call operator. I would like to remind you that all participants will be in listen-only mode and the conference is being recorded. The presentation will be followed by a Q&A session. [Operator Instructions]
At this time, it's my pleasure to hand over to Pamela Keck. Please go ahead.
Pamela Keck
Welcome, everyone, and thank you for joining us. With me today is Dr. Selwyn Ho, CEO of Medigene. Today, we announced financial results for the year ended December 31, 2023. You can access the press release on the Investor Relations page of our website at medigene.com. Before we get started, let's quickly run through the forward-looking statements. Please note that as a part of our discussion today, management will be making forward-looking statements. Also, we believe our expectations are based on reasonable assumptions. By their very nature, forward-looking statements involve risks and uncertainties that may be influenced by factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. Any forward-looking statements made on the call reflect the knowledge and information available at the time of this call. The company undertakes no obligation to update forward-looking statements.
With that, I'll hand the call over to Selwyn.
Selwyn Ho
Thank you, Pamela. Good morning, good afternoon everyone, and thank you for joining Medigene's full year 2023 earnings call. I look forward to reflecting on the past year and its achievements as we continue Medigene's journey and as we look ahead to all that we aim to achieve in 2024. Cancer remains a leading cause of death worldwide. Over the past decades, cancer research efforts have contributed to major breakthroughs, arguably most notably in immunotherapy, impacting patients lives in a profoundly positive manner. Despite these advancements, significant challenges remain, in particular regarding treatment options for patients with solid tumors. Cell therapies, such as T cell receptor engineered T cell therapies, or TCR-T therapies for short, represent one of a few promising treatments with the potential for a curative therapy for solid cancers....
Read the full article on Seeking Alpha
For further details see:
Medigene AG (MDGEF) Full Year 2023 Earnings Call Transcript